The anti-tumor effect was dependent on CD8+ T cells, supporting the concept that the depletion of tumor-associated myeloid cells mitigates immunosuppression and enhances the efficacy of T-cell targeting immunotherapies. This evidence concerns the gene CD8A and neoplasm.